![conference banner](/images/conference-banner.jpeg)
Abstract
Magnetic Resonance Imaging (MRI) has established itself as the optimal method for assessing local staging in patients with rectal cancer. This is due to several factors including, most importantly, the ability to accurately delineate the mesorectal fascia and thus determine which rectal tumours threaten the circumferential resection margin (CRM). It is also able to assess depth of tumour penetration into the mesorectum and thus identify those tumours considered high risk for disease recurrence. MRI is the optimal imaging modality to assess local nodal involvement and extramural venous invasion, which has now been recognised as a poor prognostic factor for both local recurrence and overall survival rates. The use of MRI for evaluating tumours both during and after pre-operative therapies is of increasing importanceand can influence the timing of surgery if patients undergo pathological complete response or show aggressive disease warranting more intensive treatment. This review examines the current status of MRI in the local staging and management of rectal cancer. The focus of the review is to identify the important prognostic features demonstrated on MRI and to assess the influence of these tumour characteristics on treatment decision-making.
Keywords: Magnetic resonance imaging, Rectal Cancer, Local Staging, Prognostic Factors, Mesorectum.
Current Cancer Therapy Reviews
Title:The Role of MRI in Treatment Planning for Rectal Cancer - A Review
Volume: 9 Issue: 2
Author(s): R.K. Bott, M. Chand, G.F. Nash, R.I. Swift and G. Brown
Affiliation:
Keywords: Magnetic resonance imaging, Rectal Cancer, Local Staging, Prognostic Factors, Mesorectum.
Abstract: Magnetic Resonance Imaging (MRI) has established itself as the optimal method for assessing local staging in patients with rectal cancer. This is due to several factors including, most importantly, the ability to accurately delineate the mesorectal fascia and thus determine which rectal tumours threaten the circumferential resection margin (CRM). It is also able to assess depth of tumour penetration into the mesorectum and thus identify those tumours considered high risk for disease recurrence. MRI is the optimal imaging modality to assess local nodal involvement and extramural venous invasion, which has now been recognised as a poor prognostic factor for both local recurrence and overall survival rates. The use of MRI for evaluating tumours both during and after pre-operative therapies is of increasing importanceand can influence the timing of surgery if patients undergo pathological complete response or show aggressive disease warranting more intensive treatment. This review examines the current status of MRI in the local staging and management of rectal cancer. The focus of the review is to identify the important prognostic features demonstrated on MRI and to assess the influence of these tumour characteristics on treatment decision-making.
Export Options
About this article
Cite this article as:
Bott R.K., Chand M., Nash G.F., Swift R.I. and Brown G., The Role of MRI in Treatment Planning for Rectal Cancer - A Review, Current Cancer Therapy Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/1573394711309020003
DOI https://dx.doi.org/10.2174/1573394711309020003 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore the cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the ...read more
Current progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes
Current Genomics Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry 1,3,4-Oxadiazoles as Potential Pharmacophore for Cytotoxic Potentiality: A Comprehensive Review
Current Topics in Medicinal Chemistry NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Homology Modeling of Human Nicotinamide/Nicotinic Acid Mononucleotide Adenylyltransferase 2: Insights into Isoenzyme-Specific Differences Using Molecular Docking Simulatons
Letters in Drug Design & Discovery Gene Modified Cell Transplantation for Vascular Regeneration
Current Gene Therapy The PI3 Kinase Signaling Pathway in Prostate Cancer
Current Cancer Drug Targets The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Platelet-Rich and Platelet-Poor Plasma Might Play Supportive Roles in Cancer Cell Culture: A Replacement for Fetal Bovine Serum?
Anti-Cancer Agents in Medicinal Chemistry Editorial
Current Medical Imaging Microscopic Evidence of the Behavior of pH-sensitive Food-grade Polymeric Delivery Systems
Current Nutraceuticals The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer
Current Cancer Drug Targets Mechanism of a Novel Camptothecin-Deoxycholic Acid Derivate Induced Apoptosis against Human Liver Cancer HepG2 Cells and Human Colon Cancer HCT116 Cells
Recent Patents on Anti-Cancer Drug Discovery Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Aberrant DNA Methylation and Prostate Cancer
Current Genomics Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design